An observational study in Arthritis Foot, Trauma Injury and Deformity; Bone, sponsored by Artoss Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-13.
Sponsored by Artoss Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Accidental Injuries with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Accidental Injuries · United States.
Among the 58 studies in Accidental Injuries with a site in United States, this one is the 9th largest by enrollment of the 21 observational ones that give a count, is one of 8 that started in 2020, is one of 21 observational ones, and was the 27th registered.
128 studies on the registry are indexed under Accidental Injuries; 39 are open to participants now.
Browse Accidental Injuries studies →17 of the 58 studies in Accidental Injuries with a site in United States are open now. Recruiting first, the newest first:
The Metis Foundation · Sites in United States
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
Boston Medical Center · Sites in United States
Ages 18+
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Accidental Injuries studies recruiting now, 11 (46%) set no upper age limit and 6 (25%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 170 across 59 observational studies indexed under Accidental Injuries.
Median enrollment 72 across the 37 interventional studies, 124 across the 21 observational. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 58 have an industry lead sponsor. The 10 most frequent:
Artoss Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Artoss Inc. has 1 study filed under Accidental Injuries — fewer than ten, so there is no comparison to draw.
10 of the studies in Accidental Injuries with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527599University of Wisconsin, MadisonScreening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention | 2026-12 |
| NCT06812247Boston Medical CenterTherapy Dog Visits for Patients Hospitalized With Traumatic Injuries | 2026-12 |
| NCT02577731University of FloridaHematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury | 2026-12-28 |
| NCT05794165Bryan CottonAntithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism | 2027-04 |
| NCT06793644Dartmouth-Hitchcock Medical CenterStudy of ICG Fluorescence Imaging in Open Fracture and Infection Patients | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 58 studies in Accidental Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective registry was designed as an observational study to ascertain how commercially available NanoBone products are being used by surgeons performing foot and ankle surgery which involves bone grafting, as well as determining relevant patient outcomes.
This multicenter prospective patient registry was developed with the aim of documenting how surgeons are utilizing NanoBone products in foot and ankle surgery along with relevant patient outcomes. These outcomes include radiographic measures such as fusion or graft consolidation success, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments.
The primary objective of this study is to document and analyze the use of NanoBone products in foot and ankle surgery (as a stand-alone bone graft, no other local bone, autograft, bone graft substitute, or biologic product used) and determine both radiographic success and clinical outcomes. All product related adverse events will be documented, tabulated, and summarized.
All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.
Other: NanoBone Bone Graft Substitute
Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
Also known as: nanoHA-SiO2
Radiographic Success
Fusion/Graft Consolidation: Evidence of bony (osseous) bridging between the graft material and the patient's bone in the segment requiring fusion or reconstruction.
Time frame: 6-months
Safety Evaluation
Occurrence of Complications or Adverse Events
Time frame: 6-months
Clinical Success
Change from baseline in Visual Analog Scale (VAS) pain score (0=no pain, 10=worst possible pain
Time frame: 6-months
Function
Change from baseline in Foot and Ankle Ability Measure (FAAM)
Time frame: 6-months
Ran from Aug 2020 to primary completion in May 2024, 45 months.
Of 39 observational studies under Accidental Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's 45 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Artoss Inc.